12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Diazoxide choline controlled release: Phase IIb data

In a double-blind Phase IIb trial in 90 patients, DCCR met the primary endpoint of significantly reducing triglycerides, with a 30% placebo-controlled median reduction at week 8. The company said no "meaningful" increase in LDL-C was observed...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >